Myriad Genetics Melanoma Test Gets Final LCD

Medicare contractor Palmetto GBA has issued a final local coverage determination (LCD) for Myriad Genetics’ myPath Melanoma test.

Myriad’s 23-gene expression signature test helps doctors differentiate malignant from benign biopsies. Palmetto’s MolDx program has agreed to cover myPath Melanoma for the “diagnosis or exclusion of melanoma” when a board-certified dermatopathologist orders it; when the biopsy can’t be definitively classified as benign or malignant based on standard clinical and histopathological features; and when, the patient will have to endure another biopsy because of this uncertain classification.

Source: https://www.genomeweb.com/molecular-diagnostics/myriad-genetics-melanoma-test-gets-final-lcd